Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Bladder Cancer, November 2024

Free Subscription


Abstracts

Retrieve all available abstracts of the following 252 articles:
HTML format


 

Single Articles

  1. DENG H, Ning J, Ruan Y, Yu W, et al
    TNFRSF11B promotes the progression of bladder cancer through PI3K/AKT signaling pathway.
    Mol Cell Probes. 2024 Oct 29:101989. doi: 10.1016/j.mcp.2024.101989.
    PubMed    
    Abstract available

  2. YAN L, Luo G, Han C, Meng J, et al
    Exploring the oncogenic role of RGS19 in bladder cancer progression and prognosis.
    Acta Histochem. 2024;126:152212.
    PubMed    
    Abstract available

  3. SHIN D, Kim C, Chae Y, Yun T, et al
    Successful Management of Incompletely Resected Transitional Cell Carcinoma with Sorafenib Tosylate in a Dog.
    J Am Anim Hosp Assoc. 2024;60:275-279.
    PubMed    
    Abstract available

  4. SACHAN A, Nayyar R, Pethe S, Singh P, et al
    A 3-arm randomized control trial to compare the efficacy of re-circulant hyperthermic intravesical chemotherapy versus conventional intravesical mitomycin C and BCG therapy for intermediate-risk non-muscle invasive bladder cancer.
    World J Urol. 2024;42:609.
    PubMed    
    Abstract available

  5. ACHARD V, Huddart R
    Chemoradiation therapy for Nonmetastatic Muscle-Invasive Bladder Cancer: Still the Only Bladder Preservation Treatment in 2024.
    Int J Radiat Oncol Biol Phys. 2024 Sep 27:S0360-3016(24)03331.
    PubMed    


  6. NADIMI PARASHKOUHI S, Karimzadeh I, Rezvani A, Abbasian H, et al
    Cost-Utility Analysis of Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Chemotherapy Regimen in Comparison With Gemcitabine and Cisplatin Chemotherapy Regimen in the Treatment of Patients With Muscle Invasive Bladder Cancer in Iran.
    Value Health Reg Issues. 2024 Oct 30:101051. doi: 10.1016/j.vhri.2024.101051.
    PubMed    
    Abstract available

  7. GAYLIS FD, Emond B, Manceur AM, Tardif-Samson A, et al
    Adherence to First-Line Intravesical Bacillus Calmette-Guerin Therapy in the Context of Guideline Recommendations for US Patients With High-Risk Non-muscle Invasive Bladder Cancer.
    J Health Econ Outcomes Res. 2024;11:109-117.
    PubMed    
    Abstract available

  8. TIAN J, Gao M, Zhu J, Xu H, et al
    Platelets camouflaged nanovehicle improved bladder cancer immunotherapy by triggering pyroptosis.
    Theranostics. 2024;14:6692-6707.
    PubMed    
    Abstract available

  9. LI M, Cui Y, Qi Q, Liu J, et al
    SPOP downregulation promotes bladder cancer progression based on cancer cell-macrophage crosstalk via STAT3/CCL2/IL-6 axis and is regulated by VEZF1.
    Theranostics. 2024;14:6543-6559.
    PubMed    
    Abstract available

  10. LI Y, Zhang Y, Feng N, Yu F, et al
    Three-in-One Nanozyme for Radiosensitization of Bladder Cancer.
    Int J Nanomedicine. 2024;19:10873-10883.
    PubMed    
    Abstract available

  11. HUANG J, Luo Y, Wang Y, Wang S, et al
    Silencing CCT3 induces ferroptosis through the NOD1-NF-kappaB signaling pathway in bladder cancer.
    Sci Rep. 2024;14:26188.
    PubMed    
    Abstract available

  12. CHIANG TW, Chang LW, Chiang FF, Li JR, et al
    Colon Cancer With Bladder Invasion: A Single Center Experience.
    In Vivo. 2024;38:2990-3001.
    PubMed    
    Abstract available

  13. IGUCHI R, Inoue K
    Distal preservation and retrograde resection of the anterior vaginal wall in female robot-assisted radical cystectomy.
    Asian J Endosc Surg. 2025;18:e13399.
    PubMed    
    Abstract available

  14. MACKENZIE NJ, Zimmermann K, Nicholls C, Perera MP, et al
    Altered immunophenotypic expression in the peripheral bladder cancer immune landscape.
    Immunol Cell Biol. 2024 Oct 30. doi: 10.1111/imcb.12829.
    PubMed    
    Abstract available

  15. RUSSELL B, Hagberg O, Haggstrom C, Holmberg L, et al
    The difficulty of studying the association between pathway delays and survival in cancer - an example from bladder cancer.
    Scand J Urol. 2024;59:181-184.
    PubMed    
    Abstract available

  16. LIU GL, Luo H, Liang DD, Zhong L, et al
    Comprehensive Analysis of Prognostic Alternative Splicing Signatures in Tumor Immune Infiltration in Bladder Cancer.
    Recent Pat Anticancer Drug Discov. 2024.
    PubMed    
    Abstract available

  17. LONG C, Shi H, Li J, Chen L, et al
    The diagnostic accuracy of urine-derived exosomes for bladder cancer: a systematic review and meta-analysis.
    World J Surg Oncol. 2024;22:285.
    PubMed    
    Abstract available

  18. LI Y, Piao C, Kong C
    Stearoyl CoA desaturase inhibition can effectively induce apoptosis in bladder cancer stem cells.
    Cancer Cell Int. 2024;24:357.
    PubMed    
    Abstract available

  19. JIAO P, Wu S, Yang R, Ni X, et al
    Deep Learning Predicts Lymphovascular Invasion Status in Muscle Invasive Bladder Cancer Histopathology.
    Ann Surg Oncol. 2024 Oct 29. doi: 10.1245/s10434-024-16422.
    PubMed    
    Abstract available

  20. TAKEUCHI M, Higaki A, Kojima Y, Ono K, et al
    Diagnostic significance of peritumoral enhancement in distinguishing between muscle-invasive and non-muscle-invasive bladder cancer.
    Abdom Radiol (NY). 2024 Oct 30. doi: 10.1007/s00261-024-04658.
    PubMed    
    Abstract available

  21. SHI X, Zheng W, He B, Huang L, et al
    UPLC-Q-TOF/MS-based urine metabolomics for the diagnosis and staging of bladder cancer.
    Clin Chim Acta. 2024 Oct 27:120022. doi: 10.1016/j.cca.2024.120022.
    PubMed    
    Abstract available

  22. AMMAR E, Al-Mudallal N, Abbas SM
    Cytotoxic Effect of Stenotrophomonas maltophilia Isolated from Prostate and Bladder Cancer Patients in Iraq.
    Asian Pac J Cancer Prev. 2024;25:3701-3705.
    PubMed    
    Abstract available

  23. MA G, Jia H, Li Z, Zhang X, et al
    Gefitinib Reverses PD-L1-Mediated Immunosuppression Induced by long-term Glutamine blockade in Bladder Cancer.
    Cancer Immunol Res. 2024 Oct 29. doi: 10.1158/2326-6066.CIR-24-0039.
    PubMed    
    Abstract available

  24. ZHANG W, Guo G, Li X, Lin J, et al
    A bibliometric analysis of bladder cancer and microRNA research: Trends and advances from 2008 to 2022.
    Medicine (Baltimore). 2024;103:e40289.
    PubMed    
    Abstract available

  25. YOU C, Zhu Y, Zhu J, Xu Z, et al
    Strength in Numbers: A Giant NIR-II AIEgen with One-for-All Phototheranostic Features for Exceptional Orthotopic Bladder Cancer Treatment.
    Angew Chem Int Ed Engl. 2024 Oct 29:e202417865. doi: 10.1002/anie.202417865.
    PubMed    
    Abstract available

  26. BRANZ A, Matek C, Lange F, Bahlinger V, et al
    HLA-G expression associates with immune evasion muscle-invasive urothelial cancer and drives prognostic relevance.
    Front Immunol. 2024;15:1478196.
    PubMed    
    Abstract available

  27. HUANG A, Zhao Y, Guan F, Zhang H, et al
    Performance of a HER2 testing algorithm tailored for urothelial bladder cancer: A Bi-centre study.
    Comput Struct Biotechnol J. 2024;26:40-50.
    PubMed    
    Abstract available

  28. LIU C, Liu J, Liu G, Song Y, et al
    Clitoria ternatea L. flower-derived anthocyanins and flavonoids inhibit bladder cancer growth by suppressing SREBP1 pathway-mediated fatty acid synthesis.
    Acta Biochim Biophys Sin (Shanghai). 2024 Oct 29. doi: 10.3724/abbs.2024192.
    PubMed    
    Abstract available

  29. SHAN L, Xu H, Piao C, Liu Z, et al
    Nomogram for the Pathological Complete Response After Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer Patients.
    Ann Surg Oncol. 2024 Oct 28. doi: 10.1245/s10434-024-16429.
    PubMed    
    Abstract available

  30. TATENUMA T, Matsukawa T, Goto T, Jiang G, et al
    GULP1 as a Downstream Effector of the Estrogen Receptor-beta Modulates Cisplatin Sensitivity in Bladder Cancer.
    Cancer Genomics Proteomics. 2024;21:557-565.
    PubMed    
    Abstract available

  31. WU N, Wang J, Fan M, Liang Y, et al
    Non-glycanated DeltaDCN isoform in muscle invasive bladder cancer mediates cancer stemness and gemcitabine resistance.
    Cell Oncol (Dordr). 2024 Oct 28. doi: 10.1007/s13402-024-00998.
    PubMed    
    Abstract available

  32. WEI Z, Bai X, Xv Y, Chen SH, et al
    A radiomics-based interpretable machine learning model to predict the HER2 status in bladder cancer: a multicenter study.
    Insights Imaging. 2024;15:262.
    PubMed    
    Abstract available

  33. SOLEDER S, Gengenbacher N, Mogler C, Eckstein M, et al
    Development of a novel immunocompetent murine tumor model for urothelial carcinoma using in vivo electroporation.
    Sci Rep. 2024;14:25619.
    PubMed    
    Abstract available

  34. AN S, Shi L, Liu Y, Ren L, et al
    Comparison of Extracorporeal and Intracorporeal Urinary Diversion after Robot-Assisted Radical Cystectomy for Bladder Cancer: A Meta-Analysis.
    Am J Mens Health. 2024;18:15579883241274866.
    PubMed    
    Abstract available

  35. BUELL M, Hu B
    Rapid onset severe hyperkalemia during robotic radical cystectomy: a case report.
    Can J Urol. 2024;31:12026-12029.
    PubMed    
    Abstract available

  36. STEFFENS D, Koh C, Hirst N, Cole R, et al
    Prehabilitation in patients undergoing bladder cancer surgery - A systematic review and meta-analysis.
    Can J Urol. 2024;31:12004-12012.
    PubMed    
    Abstract available

  37. JOTATSU Y, Arbiser JL, Moriwaki M, Hirata Y, et al
    Dibenzolium induces apoptosis and inhibits epithelial-mesenchymal transition (EMT) in bladder cancer cell lines.
    Sci Rep. 2024;14:25501.
    PubMed    
    Abstract available

  38. BAANA M, Arkwazi M, Zhao Y, Ofagbor O, et al
    Using artificial intelligence for bladder cancer detection during cystoscopy and its impact on clinical outcomes: a protocol for a systematic review and meta-analysis.
    BMJ Open. 2024;14:e089125.
    PubMed    
    Abstract available

  39. ZHANG J, Xu H, He Y, Zheng X, et al
    Inhibition of KDM4A restricts SQLE transcription and induces oxidative stress imbalance to suppress bladder cancer.
    Redox Biol. 2024;77:103407.
    PubMed    
    Abstract available

  40. TURAL D, Arslan C, Selcukbiricik F, Olmez OF, et al
    Immune Checkpoint Blockade Therapies Efficacy and Toxicity in Patients With Impaired Renal Function in Metastatic Bladder Cancer.
    Clin Genitourin Cancer. 2024;22:102228.
    PubMed    
    Abstract available

  41. GUO Y, Zhang Y, Mao S, Zhang W, et al
    Risk of subsequent primary cancers in bladder cancer survivors.
    Clin Exp Med. 2024;24:247.
    PubMed    
    Abstract available

  42. RUSSO F, Esposito S, Tripodi L, Pandolfo SD, et al
    Insights into Porphyromonas somerae in Bladder Cancer Patients: Urinary Detection by ddPCR.
    Microorganisms. 2024;12:2049.
    PubMed    
    Abstract available

  43. PURPUROWICZ P, Kaminski TW, Kordan W, Korzekwa A, et al
    A Pilot Study of the Role of Semaphorin 4A (sema4A) and 3C (sema3C) in Non-Muscle-Invasive Bladder Cancer (NMIBC).
    Biomedicines. 2024;12:2407.
    PubMed    
    Abstract available

  44. MAGRI V, Marino L, Del Giudice F, De Meo M, et al
    Blood Extracellular Vesicles Beyond Circulating Tumour Cells: A Valuable Risk Stratification Biomarker in High-Risk Non-Muscle-Invasive Bladder Cancer Patients.
    Biomedicines. 2024;12:2359.
    PubMed    
    Abstract available

  45. MIN K, Zheng CM, Kim S, Kim H, et al
    Differential Urinary Microbiome and Its Metabolic Footprint in Bladder Cancer Patients Following BCG Treatment.
    Int J Mol Sci. 2024;25:11157.
    PubMed    
    Abstract available

  46. DANISHUDDIN, Haque MA, Khan S, Kim JJ, et al
    Molecular Landscape of Bladder Cancer: Key Genes, Transcription Factors, and Drug Interactions.
    Int J Mol Sci. 2024;25:10997.
    PubMed    
    Abstract available

  47. GUPTA A, Verma S, Gupta S
    Comparison between N-803 and Erdafitinib in Bacillus Calmette-Guerin-Unresponsive Non-Muscle-Invasive Bladder Cancer.
    Cancers (Basel). 2024;16:3445.
    PubMed    
    Abstract available

  48. SUNNETCI KM, Oguz FE, Ekersular MN, Gulenc NG, et al
    Comparative Bladder Cancer Tissues Prediction Using Vision Transformer.
    J Imaging Inform Med. 2024 Oct 25. doi: 10.1007/s10278-024-01228.
    PubMed    
    Abstract available

  49. LI H, Sui Y, Tao Y, Cao J, et al
    Coupling Habitat Radiomic Analysis with the Diversification of the Tumor ecosystem: Illuminating New Strategy in the Assessment of Postoperative Recurrence of Non-Muscle Invasive Bladder Cancer.
    Acad Radiol. 2024 Oct 24:S1076-6332(24)00685-8. doi: 10.1016/j.acra.2024.
    PubMed    
    Abstract available

  50. SUN S, Li H, Liu S, Xie X, et al
    Long noncoding RNA UCA1 inhibits epirubicin-induced apoptosis by activating PPARalpha-mediated lipid metabolism.
    Exp Cell Res. 2024;442:114271.
    PubMed    
    Abstract available

  51. WEI W, Wang S, Hu M, Tong X, et al
    Impact of multi-parameter images obtained from dual-energy CT on radiomics to predict pathological grading of bladder urothelial carcinoma.
    Abdom Radiol (NY). 2024;49:4324-4333.
    PubMed    
    Abstract available

  52. BERTZ S, Bahlinger V, Lange F, Hartmann A, et al
    [Muscle-invasive and metastatic urothelial carcinoma of the urinary bladder : Current state of histopathologic, molecular, and immunologic prognostic and predictive factors].
    Pathologie (Heidelb). 2024;45:363-370.
    PubMed    
    Abstract available

  53. PARK JH, Kim M, Yoon J, Park I, et al
    Tumor necrosis in magnetic resonance imaging predicts urothelial carcinoma with squamous differentiation in muscle-invasive bladder carcinoma.
    Abdom Radiol (NY). 2024;49:4341-4351.
    PubMed    
    Abstract available

  54. BAHLINGER V, Stoehr R, Hartmann A, Hes O, et al
    Small cell neuroendocrine carcinoma and poorly differentiated rhabdomyosarcomas of the urinary bladder in adults-A comparative analysis in favor of a common histogenesis.
    Virchows Arch. 2024;485:615-623.
    PubMed    
    Abstract available

  55. DENG H, Ji G, Ma J, Cai J, et al
    RNF19A inhibits bladder cancer progression by regulating ILK ubiquitination and inactivating the AKT/mTOR signalling pathway.
    Biol Direct. 2024;19:102.
    PubMed    
    Abstract available

  56. XU H, Chen Y, Ye L, Zheng H, et al
    [Application of Magnetic Resonance Imaging Report Combined With VI-RADS Bi-Parametric and Multi-Parametric Scoring Systems in Bladder Cancer Diagnosis].
    Sichuan Da Xue Xue Bao Yi Xue Ban. 2024;55:1071-1077.
    PubMed    
    Abstract available

  57. DENG J, Zhang M, Yang M, Zhang P, et al
    [Clinicopathological Features and Outcomes of Perioperative Treatment for Small Cell Carcinoma of the Bladder].
    Sichuan Da Xue Xue Bao Yi Xue Ban. 2024;55:1078-1084.
    PubMed    
    Abstract available

  58. SHENG H, Gu J, Huang Y, Kolat D, et al
    Cuproptosis-related signature predicts prognosis and indicates tumor immune infiltration in bladder cancer.
    Transl Androl Urol. 2024;13:2280-2293.
    PubMed    
    Abstract available

  59. CHEN Z, Zhang Y, Chen T
    Prognostic value of neutrophil to lymphocyte ratio for patients with bladder cancer undergoing radical cystectomy: a systematic review and meta-analysis.
    Front Oncol. 2024;14:1463173.
    PubMed    
    Abstract available

  60. HUANG J, Lin L, Mao D, Hua R, et al
    Prognostic value of neutrophil-to-lymphocyte ratio in patients with non-muscle-invasive bladder cancer with intravesical Bacillus Calmette-Guerin immunotherapy: a systematic review and meta-analysis.
    Front Immunol. 2024;15:1464635.
    PubMed    
    Abstract available

  61. FITZPATRICK M, Yankelevich GR, Drerup J, Grubb RL, et al
    First Reported Case of Bronchoperitoneal Fistula From Bladder Cancer Metastasis Treated With the Novel Utilisation of an Endobronchial Valve.
    Cureus. 2024;16:e71025.
    PubMed    
    Abstract available

  62. MONJARAS-AVILA CU, Luque-Badillo AC, Bacon JVM, Wyatt AW, et al
    A novel approach to engineering three-dimensional bladder tumor models for drug testing.
    Sci Rep. 2024;14:26883.
    PubMed    
    Abstract available

  63. HO JN, Byun SS, Kim D, Ryu H, et al
    Dasatinib induces apoptosis and autophagy by suppressing the PI3K/Akt/mTOR pathway in bladder cancer cells.
    Investig Clin Urol. 2024;65:593-602.
    PubMed    
    Abstract available

  64. MOTLAGHZADEH S, Tabatabaei F, Eshragh F, Tavakoli A, et al
    Association of viral infection with bladder cancer: A systematic review and meta-analysis.
    Pathol Res Pract. 2024;264:155633.
    PubMed    
    Abstract available

  65. KONTA S, Hashimoto K, Shindo T, Kobayashi K, et al
    Ideal cystoscopic interval after nephroureterectomy in patients with upper tract urothelial carcinoma.
    World J Urol. 2024;42:629.
    PubMed    
    Abstract available

  66. SCILIPOTI P, Moschini M, de Angelis M, Afferi L, et al
    The role of re-transurethral resection of bladder tumor in patients with TaHG non muscle invasive bladder cancer.
    World J Urol. 2024;42:630.
    PubMed    
    Abstract available

  67. ZOU Y, Yu J, Cai L, Chen C, et al
    Prediction of muscular-invasive bladder cancer using multi-view fusion self-distillation model based on 3D T2-Weighted images.
    Biomed Tech (Berl). 2024 Nov 6. doi: 10.1515/bmt-2024-0333.
    PubMed    
    Abstract available

  68. ZENG YK, Zhang KY, Xing JC, Li YB, et al
    Pleomorphic rhabdomyosarcoma of the adult bladder: a case report.
    J Med Case Rep. 2024;18:523.
    PubMed    
    Abstract available

  69. HU XC, Yu QY, Ding HP, Xiao F, et al
    Exploration on the construction of a bladder cancer prognostic model based on disulfidptosis-related lncRNAs and its clinical significance.
    Sci Rep. 2024;14:26751.
    PubMed    
    Abstract available

  70. IYER G, Tangen CM, Sarfaty M, Regazzi AM, et al
    DNA Damage Response Alterations Predict for Neoadjuvant Chemotherapy Sensitivity in Muscle-Invasive Bladder Cancer: A Correlative Analysis of the SWOG S1314 Trial.
    JCO Precis Oncol. 2024;8:e2400287.
    PubMed    
    Abstract available

  71. WATANABE M, Kawamorita N, Shiraiwa T, Sato T, et al
    Distant recurrence of non-muscle invasive bladder cancer 8 years after initial treatment.
    IJU Case Rep. 2024;7:448-453.
    PubMed    
    Abstract available

  72. AKAND M, Jatsenko T, Muilwijk T, Gevaert T, et al
    Deciphering the molecular heterogeneity of intermediate- and (very-)high-risk non-muscle-invasive bladder cancer using multi-layered -omics studies.
    Front Oncol. 2024;14:1424293.
    PubMed    
    Abstract available

  73. DIAO M, Li Y, Gao Z, Wang C, et al
    Comparison of prognosis after transurethral resection of bladder tumor between solitary and multiple bladder cancers.
    Medicine (Baltimore). 2024;103:e40314.
    PubMed    
    Abstract available

  74. KIANMEHR S, Vahabirad M, Seghatoleslam A, Sadeghi E, et al
    Prognostic Value of TGF-beta Expression in Bladder Cancer: A Systematic Review and Meta-analysis.
    Urol Res Pract. 2024;50:148-153.
    PubMed    
    Abstract available

  75. KURAL S, Pathak AK, Singh S, Jain G, et al
    Prospective Assessment of VI-RADS with Muscle Invasion in Urinary Bladder Cancer and Its Implication on Re-Resection/Restaging TURBT Patients.
    Ann Surg Oncol. 2024 Nov 4. doi: 10.1245/s10434-024-16424.
    PubMed    
    Abstract available

  76. ZHANG Z, Wu Z, Shen C, Liu Z, et al
    Establishing a Murine Superficial Bladder Cancer Model via an Intravesical Cell Administration Technique.
    J Vis Exp. 2024;.
    PubMed    
    Abstract available

  77. BEEREN I, Koops C, van der Heijden AG, Aben KKH, et al
    Lifestyle Advice to Patients with Bladder Cancer: A National Survey of Dutch Urologists.
    Bladder Cancer. 2024;10:215-220.
    PubMed    
    Abstract available

  78. DE JONG JJ, de Jong FC, van der Made ACJ, van Casteren NJ, et al
    A Molecular Urine Assay to Detect Recurrences During Surveillance of High-Risk Non-Muscle Invasive Bladder Cancer.
    Bladder Cancer. 2024;10:233-242.
    PubMed    
    Abstract available

  79. SINGH P, Ballas L, Sonpavde GP, Chen RC, et al
    Eligibility and Endpoints for Clinical Trials in Trimodality Therapy for Bladder Cancer.
    Bladder Cancer. 2024;10:199-213.
    PubMed    
    Abstract available

  80. GURRAM S, Rathi N
    Device-Assisted Therapy in Non-Muscle-Invasive Bladder Cancer.
    Bladder Cancer. 2024;10:167-182.
    PubMed    
    Abstract available

  81. DING JY, Pan TT, Lu XJ, You XM, et al
    Effects of peer-led education on knowledge, attitudes, practices of stoma care, and quality of life in bladder cancer patients after permanent ostomy.
    Front Med (Lausanne). 2024;11:1431373.
    PubMed    
    Abstract available

  82. PENG L, Shang W, Guo P, He K, et al
    Correction: Phage Display-Derived Peptide-Based Dual-Modality Imaging Probe for Bladder Cancer Diagnosis and Resection Postinstillation: A Preclinical Study.
    Mol Cancer Ther. 2024;23:1681.
    PubMed    


  83. CHANG L, Xu X, Wu G, Cheng L, et al
    Predicting Preoperative Pathologic Grades of Bladder Cancer Using Intravoxel Incoherent Motion and Amide Proton Transfer-Weighted Imaging.
    Acad Radiol. 2023 Oct 26:S1076-6332(23)00533-0. doi: 10.1016/j.acra.2023.
    PubMed    
    Abstract available

  84. TAN WS, O'Donnell M, Li R, Kamat AM, et al
    Reply to Wen-Wei Sung's Letter to the Editor re: Wei Shen Tan, Ian M. McElree, Facundo Davaro, et al. Sequential Intravesical Gemcitabine and Docetaxel Is an Alternative to Bacillus Calmette-Guerin for the Treatment of Intermediate-risk Non-muscle-inv
    Eur Urol Oncol. 2023 Oct 26:S2588-9311(23)00225.
    PubMed    


  85. OLIVER T, Ramiah D, Mmereki D, Hugo M, et al
    Bladder cancer: a retrospective audit at a single radiation oncology unit of an academic hospital in Johannesburg, South Africa.
    J Egypt Natl Canc Inst. 2024;36:34.
    PubMed    
    Abstract available

  86. XIE G, Qi T, Yao Y, Feng D, et al
    MFAP3L predicts tumor microenvironment status, molecular subtypes and clinical benefit in patients with bladder cancer.
    Sci Rep. 2024;14:26545.
    PubMed    
    Abstract available

  87. YANG H, Jin C, Li J, Zhang Z, et al
    Causal relationship between bladder cancer and gut microbiota contributes to the gut-bladder axis: A two-sample Mendelian randomization study.
    Urol Oncol. 2024 Nov 2:S1078-1439(24)00697-5. doi: 10.1016/j.urolonc.2024.
    PubMed    
    Abstract available

  88. HUA X, Xiang D, Xu J, Zhang S, et al
    ISO-upregulated BECN1 specifically promotes LC3B-dependent autophagy and anticancer activity in invasive bladder cancer.
    Transl Oncol. 2024;51:102178.
    PubMed    
    Abstract available

  89. KAWASAKI JAI, Pinheiro LCL, da Silva IM, Miqueloto CA, et al
    BCL-2 and gamma-H2AX immunostaining profile in urothelial bladder cancer prognosis.
    Pathol Res Pract. 2024;264:155680.
    PubMed    
    Abstract available

  90. RAUTIOLA J, Martini A, Mertens LS, Skokic V, et al
    Outcomes after robot-assisted radical cystectomy with orthotopic neobladder in women.
    World J Urol. 2024;42:617.
    PubMed    
    Abstract available

  91. HUANG H, Dai Z, Jiang Z, Li X, et al
    Anti-PD-1 immunotherapy for the treatment of metastatic urothelial carcinoma in a kidney transplant recipient: a case report.
    BMC Nephrol. 2024;25:390.
    PubMed    
    Abstract available

  92. CAO Y, Feng J, Zhang Q, Deng C, et al
    Magnetic 3D macroporous MOF oriented urinary exosome metabolomics for early diagnosis of bladder cancer.
    J Nanobiotechnology. 2024;22:671.
    PubMed    
    Abstract available

  93. HAN Z, Tang Y, Yi X, Li J, et al
    Oncological outcomes of organ-sparing cystectomy versus standard radical cystectomy in male patients diagnosed with bladder cancer.
    World J Urol. 2024;42:619.
    PubMed    
    Abstract available

  94. BARKER SJ, Soylu E, Allen BC, Auron M, et al
    ACR Appropriateness Criteria(R) Pretreatment Staging of Urothelial Cancer: 2024 Update.
    J Am Coll Radiol. 2024;21.
    PubMed    
    Abstract available

  95. DOS ANJOS OLIVEIRA E, Cunha Almeida T, Nicioli da Silva G
    Oncogenic role of lncRNA SBF2-AS1 in bladder cancer.
    Gene. 2024;935:149061.
    PubMed    
    Abstract available

  96. SONG YX, Peng Y, Qin CP, Xu T, et al
    [Current applications and translational prospects of omics technologies in urothelial carcinoma].
    Zhonghua Wai Ke Za Zhi. 2024;62:1058-1063.
    PubMed    
    Abstract available

  97. NGUYEN DD, Hooper WF, Liu W, Chu TR, et al
    The interplay of mutagenesis and ecDNA shapes urothelial cancer evolution.
    Nature. 2024;635:219-228.
    PubMed    
    Abstract available

  98. GRAFF P, Pommier P, Minsat M, Crehange G, et al
    [Practice-changing trials: Urological radiation oncology].
    Cancer Radiother. 2024;28.
    PubMed    
    Abstract available

  99. MOTIE FM, Soltani Howyzeh M, Ghanbariasad A
    Synergic effects of DL-limonene, R-limonene, and cisplatin on AKT, PI3K, and mTOR gene expression in MDA-MB-231 and 5637 cell lines.
    Int J Biol Macromol. 2024;280.
    PubMed    
    Abstract available

  100. TIBURCIO-JUNIOR E, Carrazzoni PG, Tenorio-Filho F, Pontes NE, et al
    Prolonged detection of BPV2 in urine and blood of papillomatosis-affected cattle not grazing bracken fern.
    Vet Res Commun. 2024;48:4061-4065.
    PubMed    
    Abstract available

  101. SHARAN KC, Srinivasan R, Uppal R, Rohilla M, et al
    Utility of UroVysion Fluorescence in situ Hybridization in Improving the Diagnostic Performance of Urine Cytology.
    Acta Cytol. 2024;68:423-435.
    PubMed    
    Abstract available

  102. RUSSELL BM, Fein DEC, Bellmunt J
    Determining fitness for enfortumab vedotin and pembrolizumab in metastatic bladder cancer: the time to move beyond isolated comorbidity assessments.
    ESMO Open. 2024;9:103985.
    PubMed    


  103. SHANG B, Hu Z, Xie R, Wu J, et al
    Predictive Value of Neutrophil Extracellular Traps in Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer.
    Mol Carcinog. 2024 Nov 14. doi: 10.1002/mc.23844.
    PubMed    
    Abstract available

  104. KAYAMA E, Uemura M, Onagi A, Meguro S, et al
    A Novel Gene Expression Scoring System Predicts Recurrence in Non-Muscle-Invasive Bladder Cancer Patients.
    Cancer Med. 2024;13:e70349.
    PubMed    
    Abstract available

  105. ALEXANDER CE, Nathan A, Light A, Gao C, et al
    Understanding the long-term impact of the COVID-19 pandemic on non-muscle-invasive bladder cancer outcomes: 12-Month follow-up data from the international, prospective COVIDSurg Cancer study.
    BJUI Compass. 2024;5:1044-1051.
    PubMed    
    Abstract available

  106. HUGHES S, Nair R, Radia B, Mavuduru RS, et al
    Indian consensus statements on the management of small renal masses, non-muscle invasive bladder cancer and high-risk/locally advanced prostate cancer.
    BJUI Compass. 2024;5:1034-1043.
    PubMed    
    Abstract available

  107. DEOL ES, Nabavizadeh R, Lavoie RR, Dumbrava MG, et al
    Role of B7-H3 in predicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer.
    BJUI Compass. 2024;5:1052-1058.
    PubMed    
    Abstract available

  108. MANNION L, Watson V, Mullassery V, Nair R, et al
    Treatment preferences of patients with muscle invasive bladder cancer: A discrete choice experiment.
    BJUI Compass. 2024;5:1059-1068.
    PubMed    
    Abstract available

  109. AVUDAIAPPAN AP, Prabhakar P, Siretskiy R, Renshaw A, et al
    Reliability of mpMRI in diagnosing cancer prostate following intravesical BCG for bladder cancer.
    BJUI Compass. 2024;5:1090-1094.
    PubMed    
    Abstract available

  110. MIYAKE M, Iemura Y, Oda Y, Miyamoto T, et al
    Bladder preservation with concurrent chemoradiotherapy for muscle-invasive bladder cancer: Retrospective comparison of three regimens.
    Bladder (San Franc). 2024;11:e21200009.
    PubMed    
    Abstract available

  111. PENG Y, Song Y, Qin C, Du Y, et al
    Safety profiles of intravesical Bacillus Calmette-Guerin in bladder cancer.
    Hum Vaccin Immunother. 2024;20:2425529.
    PubMed    
    Abstract available

  112. HORI K, Yamada S, Murata K, Miyata H, et al
    Establishment of potent TCR-T cells specific for cisplatin-resistance related tumor-associated antigen, CLSPN using codon-optimization.
    Hum Vaccin Immunother. 2024;20:2414542.
    PubMed    
    Abstract available

  113. PRIHADI JC, Hengky A, Lionardi SK, Haruman SP, et al
    Characteristics and outcomes in bladder Leiomyoma management: a systematic review of case reports and case series from the past 20 years.
    BMC Urol. 2024;24:252.
    PubMed    
    Abstract available

  114. JIAO P, Zheng Q
    ASO Author Reflections: How to Efficiently and Accurately Predict the Lymphovascular Invasion Status of Muscle-Invasive Bladder Cancer?
    Ann Surg Oncol. 2024 Nov 13. doi: 10.1245/s10434-024-16538.
    PubMed    


  115. HOU DY, Zhang NY, Zhang P, Li XP, et al
    In vivo self-assembled bispecific fluorescence probe for early detection of bladder cancer and metastasis.
    Sci Bull (Beijing). 2024 Oct 31:S2095-9273(24)00792.
    PubMed    
    Abstract available

  116. AMIRIAN H, Franco FB, Dabiri B, Alessandrino F, et al
    Urologic Imaging of the Bladder: Cancers and Mimics.
    Urol Clin North Am. 2025;52:111-124.
    PubMed    
    Abstract available

  117. KWON WA
    FGFR Inhibitors in Urothelial Cancer: From Scientific Rationale to Clinical Development.
    J Korean Med Sci. 2024;39:e320.
    PubMed    
    Abstract available

  118. MILOWSKY MI
    Toward Curing More Patients with Bladder Cancer - A New Perioperative Strategy.
    N Engl J Med. 2024;391:1848-1849.
    PubMed    


  119. DU S, Yang Y, Wu T, Zhang L, et al
    Culture supernatant of Toxoplasma gondii tachyzoites inhibits the proliferation and metastasis of bladder cancer cells.
    Oncol Lett. 2024;29:12.
    PubMed    
    Abstract available

  120. SINGH A, Gali KV, Pai V, Hegde P, et al
    A diagnostic challenge: Eosinophilic cystitis masquerading as bladder cancer with seminal vesicle invasion.
    Asian J Urol. 2024;11:669-670.
    PubMed    


  121. AHMADI N, Shafee H, Moudi E
    Prediction of recurrence risk in patients with non-muscle-invasive bladder cancer.
    Asian J Urol. 2024;11:625-632.
    PubMed    
    Abstract available

  122. WAHEED A, Gul MH, Wardak AB, Raja HAA, et al
    Nogapendekin alfa inbakicept-PMLN: first approval milestone for BCG-unresponsive noninvasive bladder cancer: editorial.
    Ann Med Surg (Lond). 2024;86:6386-6388.
    PubMed    


  123. WANG Y, Zhao Y, Liu Q, Yang J, et al
    Identifying functional cuproptosis-related long non-coding RNAs in patients with bladder cancer.
    Transl Cancer Res. 2024;13:5178-5189.
    PubMed    
    Abstract available

  124. STORMOEN DR, Lehn S, Mouw KW, Szallasi Z, et al
    Assessing expression patterns of PTGR1, a potential biomarker for acylfulven sensitivity in urothelial carcinoma.
    Sci Rep. 2024;14:27448.
    PubMed    
    Abstract available

  125. THOMAS KR, Joshua C, Ibilibor C
    Psychological Distress in Bladder Cancer Patients: A Systematic Review.
    Cancer Med. 2024;13:e70345.
    PubMed    
    Abstract available

  126. HEARD JR, Ahdoot M, Theodorescu D, Mitra AP, et al
    Biomarkers of treatment response in bladder cancer.
    Expert Rev Mol Diagn. 2024 Nov 13:1-13. doi: 10.1080/14737159.2024.2428747.
    PubMed    
    Abstract available

  127. WATANABE A, Ogawa Y, Saeki M, Nagata T, et al
    Different Patterns of Platelet Count Fluctuation in Response to Various Anticancer Chemotherapies among Patient with Bladder Cancer.
    Case Rep Oncol. 2024;17:1277-1281.
    PubMed    
    Abstract available

  128. XIAO Z, Liu X, Wang Y, Jiang S, et al
    Comprehensive analysis of single-cell and bulk RNA sequencing reveals postoperative progression markers for non-muscle invasive bladder cancer and predicts responses to immunotherapy.
    Discov Oncol. 2024;15:649.
    PubMed    
    Abstract available

  129. LIU B, Wang K, Li Q, Xiao Z, et al
    Engineered VNP20009 expressing IL-15&15Ralpha augments anti-tumor immunity for bladder cancer treatment.
    Biomaterials. 2024;315:122951.
    PubMed    
    Abstract available

  130. LI S, Shi Y, Dong H, Guo H, et al
    Phase 2 Trial of Enfortumab Vedotin in Patients With Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma in China.
    Cancer Med. 2024;13:e70368.
    PubMed    
    Abstract available

  131. LIU L, He JH, Xiao Y
    Risk Factors of Suicide After Bladder Cancer Diagnosis and More Information to Development Nomogram.
    J Clin Nurs. 2024 Nov 11. doi: 10.1111/jocn.17539.
    PubMed    


  132. HAMADA K, Nagumo Y, Kandori S, Isoda B, et al
    Phospholipase D2 downregulates interleukin-1beta secretion from tumor-associated macrophages to suppress bladder cancer progression.
    Cancer Sci. 2024 Nov 11. doi: 10.1111/cas.16393.
    PubMed    
    Abstract available

  133. CAO J, Chen S, Wang J, Fan X, et al
    Transcription factor PRRX1-activated ANXA6 facilitates EGFR-PKCalpha complex formation and enhances cisplatin sensitivity in bladder cancer.
    Life Sci. 2024;359:123228.
    PubMed    
    Abstract available

  134. GUO W, Zhao S, Yan K, Fan Y, et al
    The potential of ESCO2 as a prognostic and immunotherapeutic marker of pan-cancer and its role in anti-PD1 treatment of bladder cancer.
    Oncology. 2024 Nov 11:1-26. doi: 10.1159/000542188.
    PubMed    
    Abstract available

  135. KURAL S, Kumar L
    ASO Author Reflections: Reevaluating Muscle Invasion in Bladder Cancer: The Role of VI-RADS in Guiding Re-resections/ Re-stage TURBT.
    Ann Surg Oncol. 2024 Nov 11. doi: 10.1245/s10434-024-16475.
    PubMed    


  136. PERSHUKOV IV
    [Drug-Eluting Stents - a Panacea for Everyone or Not? Commentary on the Paper <>].
    Kardiologiia. 2024;64:74-76.
    PubMed    
    Abstract available

  137. POTIEVSKAYA VI, Choronenko VE, Loenko VB, Rerberg AG, et al
    [Perioperative Myocardial Infarction and Successful Revascularization in Patient With Primary Metasynchronic Rectal, Gastric and Bladder Cancer].
    Kardiologiia. 2024;64:68-73.
    PubMed    
    Abstract available

  138. TANG Y, Li S, Zhu L, Yao L, et al
    Improve clinical feature-based bladder cancer survival prediction models through integration with gene expression profiles and machine learning techniques.
    Heliyon. 2024;10:e38242.
    PubMed    
    Abstract available

  139. LI Y, Shi P, Ding Y, Yao Z, et al
    Single cell analysis identified a basal cell transition state associated with the development and progression of bladder cancer.
    J Transl Med. 2024;22:1010.
    PubMed    
    Abstract available

  140. FAN L, Guo D, Zhu C, Gao C, et al
    LRRC45 accelerates bladder cancer development and ferroptosis inhibition via stabilizing NRF2 by competitively KEAP1 interaction.
    Free Radic Biol Med. 2024 Nov 8:S0891-5849(24)01023.
    PubMed    
    Abstract available

  141. LI R, Villa NY, Yu X, Johnson JO, et al
    Oncolytic immunotherapy with nivolumab in muscle-invasive bladder cancer: a phase 1b trial.
    Nat Med. 2024 Nov 9. doi: 10.1038/s41591-024-03324.
    PubMed    
    Abstract available

  142. WANG G, Peng T, Chen L, Xiong K, et al
    Mevalonate pathway inhibition reduces bladder cancer metastasis by modulating RhoB protein stability and integrin beta1 localization.
    Commun Biol. 2024;7:1476.
    PubMed    
    Abstract available

  143. SPAGNUOLO C, Mautone F, Meola AMI, Moccia S, et al
    Synergistic Combination of Quercetin and Mafosfamide in Treatment of Bladder Cancer Cells.
    Molecules. 2024;29:5176.
    PubMed    
    Abstract available

  144. CARBONELL E, Mercader C, Alfambra H, Narvaez P, et al
    The Role of Bladder-Washing Cytology as an Adjunctive Method to Cystoscopy During Follow-Up for Low-Grade TaT1 Non-Muscle-Invasive Bladder Cancer.
    Cancers (Basel). 2024;16:3708.
    PubMed    
    Abstract available

  145. AKAND M, Veys R, Ost D, Vander Eeckt K, et al
    Cohort Profile: VZNKUL-NMIBC Quality Indicators Program: A Flemish Prospective Cohort to Evaluate the Quality Indicators in the Treatment of Non-Muscle-Invasive Bladder Cancer.
    Cancers (Basel). 2024;16:3653.
    PubMed    
    Abstract available

  146. LAN K, Zhang Y, Xu Q, Zhang Y, et al
    Pyroptosis-related biotargets and network mechanisms of juglone against bladder cancer: An integrated bioinformatics and multiple machine learning.
    Asian J Surg. 2024 Nov 7:S1015-9584(24)02345.
    PubMed    


  147. RICO L, Maqueda M, Blas L, Contreras P, et al
    Anterograde placement of drug-coated balloon for ureteroileal anastomosis stricture.
    BMJ Case Rep. 2024;17:e259977.
    PubMed    
    Abstract available

  148. YONEZAKI S, Shimizu MS, Ota T, Ozasa S, et al
    Multiple Arterial Aneurysms in a Patient with Spondylitis Following Intravesical Bacillus Calmette-Guerin Administration for Bladder Cancer: A Case Report.
    J Infect Chemother. 2024 Nov 6:S1341-321X(24)00296.
    PubMed    
    Abstract available

  149. NARGIS N, Sens DA, Mehus AA
    Knockdown of Keratin 6 Within Arsenite-Transformed Human Urothelial Cells Decreases Basal/Squamous Expression, Inhibits Growth, and Increases Cisplatin Sensitivity.
    Cells. 2024;13:1803.
    PubMed    
    Abstract available

  150. ZHANG X, Peng P, Bao LW, Zhang AQ, et al
    Ubiquitin-Specific Protease 1 Promotes Bladder Cancer Progression by Stabilizing c-MYC.
    Cells. 2024;13:1798.
    PubMed    
    Abstract available

  151. KLEIN C, Mebroukine S, Madery M, Moisand A, et al
    Myeloid-Derived Suppressor Cells in Bladder Cancer: An Emerging Target.
    Cells. 2024;13:1779.
    PubMed    
    Abstract available

  152. WANG S, Yan X, Lan W, Wang Y, et al
    Genetic Alterations in Chromatin Regulatory Genes in Upper Tract Urothelial Carcinoma and Urothelial Bladder Cancer.
    Cancer Med. 2024;13:e70398.
    PubMed    
    Abstract available

  153. JIAO P, Yang R, Liu Y, Fu S, et al
    Deep learning-based computed tomography urography image analysis for prediction of HER2 status in bladder cancer.
    J Cancer. 2024;15:6336-6344.
    PubMed    
    Abstract available

  154. FEGHALY C, Challita R, Hadir HB, Mobayed T, et al
    Bladder Cancer Treatments in the Age of Personalized Medicine: A Comprehensive Review of Potential Radiosensitivity Biomarkers.
    Biomark Insights. 2024;19:11772719241297168.
    PubMed    
    Abstract available

  155. GORDON NS, McGuigan EK, Ondasova M, Knight J, et al
    Comparison and combination of mutation and methylation-based urine tests for bladder cancer detection.
    Biomark Res. 2024;12:133.
    PubMed    
    Abstract available

  156. GOYAL S, Periasamy K, Dey T, Vias P, et al
    Adjuvant Radiotherapy in Bladder Cancers: A Dosimetric Study Focusing on Ileal Conduit Sparing.
    Clin Oncol (R Coll Radiol). 2024;37:103654.
    PubMed    
    Abstract available

  157. SCILIPOTI P, Moschini M, de Angelis M, Longoni M, et al
    Risk of Metachronous Upper Tract Urothelial Carcinoma After Ureteral Stenting in Patients With Bladder Cancer.
    Clin Genitourin Cancer. 2024;22:102241.
    PubMed    
    Abstract available

  158. UHRBRAND CG, Obad DS, Jensen BT, Jensen JB, et al
    Effect of intraoperative methadone in robot-assisted cystectomy on postoperative opioid requirements: A randomized clinical trial.
    Acta Anaesthesiol Scand. 2025;69:e14545.
    PubMed    
    Abstract available

  159. HUANG S, Jia K, Shen C, Chen H, et al
    [Analysis of Clinicopathological Characteristics and Factors Affecting the Prognosis of Patients With Resectable Sarcomatoid Carcinoma of the Bladder].
    Sichuan Da Xue Xue Bao Yi Xue Ban. 2024;55:1085-1091.
    PubMed    
    Abstract available

  160. TANG H, Liu X, Ke J, Tang Y, et al
    New perspectives of exosomes in urologic malignancies - Mainly focus on biomarkers and tumor microenvironment.
    Pathol Res Pract. 2024;263:155645.
    PubMed    
    Abstract available

  161. KHAZAMIPOUR N, Oo HZ, Al-Nakouzi N, Marzban M, et al
    Transient CAR T cells with specificity to oncofetal glycosaminoglycans in solid tumors.
    EMBO Mol Med. 2024;16:2775-2794.
    PubMed    
    Abstract available

  162. BOLEK H, Yazgan SC, Yekeduz E, Urun Y, et al
    Meta-analysis of platinum chemotherapy combinations with immunotherapy in metastatic urothelial carcinoma.
    Oncologist. 2024;29:999-1002.
    PubMed    
    Abstract available

  163. MA M, Li X, Jing M, Zhang P, et al
    Enhanced Tumor-Targeted Delivery of Arginine-Rich Peptides via a Positive Feedback Loop Orchestrated by Piezo1/integrin beta1 Signaling Axis.
    Adv Sci (Weinh). 2024;11:e2409081.
    PubMed    
    Abstract available

  164. ETO S, Kato D, Saeki K, Iguchi T, et al
    Comprehensive Analysis of the Tumour Immune Microenvironment in Canine Urothelial Carcinoma Reveals Immunosuppressive Mechanisms Induced by the COX-Prostanoid Cascade.
    Vet Comp Oncol. 2024;22:500-512.
    PubMed    
    Abstract available

  165. PARK JY, Yu J, Kim CS, Baek JW, et al
    Transcutaneous electrical nerve stimulation and catheter-related bladder discomfort following transurethral resection of bladder tumour: A randomised controlled trial.
    Eur J Anaesthesiol. 2024;41:821-830.
    PubMed    
    Abstract available

  166. CHEN C, Zhang Y, Lin Y, Shen C, et al
    The prognostic significance and immune characteristics of bone morphogenetic proteins (BMPs) family: A pan-cancer multi-omics analysis.
    Technol Health Care. 2024;32:4123-4175.
    PubMed    
    Abstract available

  167. PIRAS A, D'Aviero A, Sanfratello A, Boldrini L, et al
    Stereotactic Radiotherapy for Penile Metastasis: Case Report and Systematic Literature Review.
    Oncol Res Treat. 2024;47:565-572.
    PubMed    
    Abstract available

  168. CERSOSIMO RJ
    Targeted and immunotherapy for the management of advanced urothelial carcinoma of the bladder.
    Am J Health Syst Pharm. 2024;81:1109-1123.
    PubMed    
    Abstract available

  169. YU R, Cai L, Gong Y, Sun X, et al
    MRI-Based Machine Learning Radiomics for Preoperative Assessment of Human Epidermal Growth Factor Receptor 2 Status in Urothelial Bladder Carcinoma.
    J Magn Reson Imaging. 2024 Mar 8. doi: 10.1002/jmri.29342.
    PubMed    
    Abstract available

  170. MA X, Zhang Q, He L, Liu X, et al
    Artificial intelligence application in the diagnosis and treatment of bladder cancer: advance, challenges, and opportunities.
    Front Oncol. 2024;14:1487676.
    PubMed    
    Abstract available

  171. HASSOUNEH Z, Huang G, Zhang N, Rao M, et al
    Commentary: On the Emerging Role of Innate Lymphoid Cells in Bladder Cancer.
    J Cancer Immunol (Wilmington). 2024;6:125-134.
    PubMed    


  172. XIAO Y, Xu D, Bao E, Liu Z, et al
    Identification of inflammation related gene signatures for bladder cancer prognosis prediction.
    Sci Rep. 2024;14:28867.
    PubMed    
    Abstract available

  173. DAI C, Li Q, Wang L, Zhang J, et al
    FENDRR represses Bladder Cancer Cell Proliferation, Stemness, Migration, Invasion, and EMT Process by Targeting miR-18a-5p/AFF4 Axis.
    Biochem Genet. 2024 Nov 21. doi: 10.1007/s10528-024-10944.
    PubMed    
    Abstract available

  174. AQERROUT M, Mharrach I, Anouar Tadlaoui K, Laraqui A, et al
    Adenomatous Polyposis Coli (APC) Promoter Gene Methylation in Urine-Derived DNA: A Non-invasive Biomarker for Early Bladder Cancer Detection and Tumor Aggressiveness.
    Cureus. 2024;16:e72055.
    PubMed    
    Abstract available

  175. LUO Y, Wei S, Yang J, Tan Z, et al
    Nomogram for predicting all-cause mortality and cancer-specific mortality after TURBT for non-muscle-invasive bladder cancer.
    Sci Rep. 2024;14:28759.
    PubMed    
    Abstract available

  176. LEYDERMAN M, Chandrasekar T, Grivas P, Li R, et al
    Metastasis development in non-muscle-invasive bladder cancer.
    Nat Rev Urol. 2024 Nov 20. doi: 10.1038/s41585-024-00963.
    PubMed    
    Abstract available

  177. BEIJERT IJ, Wever BMM, Hentschel AE, van den Burgt Y, et al
    Bladder cancer detection in urine by novel methylation markers.
    Sci Rep. 2024;14:28705.
    PubMed    
    Abstract available

  178. POPOV S V, Guseinov R G, Pomeshkin E V, Skryabin O N, et al
    [Comparative study of thulium and holmium laser in non-muscle invasive bladder cancer].
    Urologiia. 2024;:81-86.
    PubMed    
    Abstract available

  179. LOS M S, Makov P S, Ukharsky A V
    [Studers operation is a fight for the quality of life of the patient].
    Urologiia. 2024;:93-97.
    PubMed    
    Abstract available

  180. BAZAEV V V, Setdikova G R, Shibaev A N, Podoinitsin A A, et al
    [The case of neuroectodermal pelvic tumor with bladder invasion].
    Urologiia. 2024;:87-92.
    PubMed    
    Abstract available

  181. ABOYAN I A, Grigoriev N A, Pacus S M, Shiranov K A, et al
    [Endoscopic treatment of obliteration of the ureteral orifice after transurethral resection of bladder tumor. Rendez-vous technique].
    Urologiia. 2024;:10-13.
    PubMed    
    Abstract available

  182. DYMOV A M, Lee Yu A, Korchagin M P, Dzharimok A R, et al
    [BCG-therapy for non-muscle-invasive bladder cancer: overview of the current trends].
    Urologiia. 2024;:116-120.
    PubMed    
    Abstract available

  183. DARENKOV S P, Pronkin E A, Musaev I E, Novikov V A, et al
    [En bloc transurethral resection for non-muscle invasive bladder cancer].
    Urologiia. 2024;:83-87.
    PubMed    
    Abstract available

  184. KOBAYASHI K, Fujii N, Shimizu K, Hitaka Y, et al
    Comparative analysis of oncological outcomes between trimodal therapy and radical cystectomy in muscle-invasive bladder cancer utilizing propensity score matching.
    Jpn J Clin Oncol. 2024 Nov 20:hyae164. doi: 10.1093.
    PubMed    
    Abstract available

  185. YUCEL C, Dumanli E, Karabacak MC, Akbay EK, et al
    Prognostic Significance of the Controlling Nutritional Status (CONUT) Score in Patients with Muscle-Invasive Bladder Cancer after Radical Cystectomy.
    Urol J. 2024 Nov 16. doi: 10.22037/uj.v21i.8266.
    PubMed    
    Abstract available

  186. TAOKA R, Fukuhara H, Miyake M, Kobayashi K, et al
    Correction to: Effect of extending the period from oral administration of 5-aminolevulinic acid hydrochloride to photodynamic diagnosis during transurethral resection for non-muscle invasive bladder cancer on diagnostic accuracy and safety: a single-a
    Int J Clin Oncol. 2024 Nov 19. doi: 10.1007/s10147-024-02654.
    PubMed    


  187. YUDOVICH MS, Alzubaidi AN, Raman JD
    Artificial Intelligence can Facilitate Application of Risk Stratification Algorithms to Bladder Cancer Patient Case Scenarios.
    Clin Med Insights Oncol. 2024;18:11795549241296781.
    PubMed    
    Abstract available

  188. GOUDSCHAAL K, Azzarouali S, Visser J, Admiraal M, et al
    Clinical implementation of RTT-only CBCT-guided online adaptive focal radiotherapy for bladder cancer.
    Clin Transl Radiat Oncol. 2024;50:100884.
    PubMed    
    Abstract available

  189. STEINMETZ AR, Pierce M, Martini A, Tholomier C, et al
    Single-cell RNA sequencing analysis identifies acute changes in the tumor microenvironment induced by interferon alpha gene therapy in a murine bladder cancer model.
    Front Immunol. 2024;15:1387229.
    PubMed    
    Abstract available

  190. YANG T, Luo W, Yu J, Zhang H, et al
    Bladder cancer immune-related markers: diagnosis, surveillance, and prognosis.
    Front Immunol. 2024;15:1481296.
    PubMed    
    Abstract available

  191. LIU C, Ge H, Shen C, Hu D, et al
    NOTCH3 promotes malignant progression of bladder cancer by directly regulating SPP1 and activating PI3K/AKT pathway.
    Cell Death Dis. 2024;15:840.
    PubMed    
    Abstract available

  192. WANG KJ, Ye SZ, Jia XL, Wang KY, et al
    RON receptor tyrosine kinase as a critical determinant in promoting tumorigenic behaviors of bladder cancer cells through regulating MMP12 and HIF-2alpha pathways.
    Cell Death Dis. 2024;15:844.
    PubMed    
    Abstract available

  193. TRIMARCHI R, Migliaccio N, Bucolo GM, Abate C, et al
    Spectral CT for non-invasive evaluation of bladder cancer grade.
    Abdom Radiol (NY). 2024 Nov 19. doi: 10.1007/s00261-024-04683.
    PubMed    
    Abstract available

  194. HUANG Z, Zhang W, Huang K, Feng J, et al
    Determination of serum vitamin D in patients with renal, bladder, and prostate cancer by ultra-performance liquid chromatography-tandem mass spectrometry.
    Neoplasma. 2024;71:463-472.
    PubMed    
    Abstract available

  195. HENGKY A, Lionardi SK, Kusumajaya C
    Can artificial intelligence aid the urologists in detecting bladder cancer?
    Indian J Urol. 2024;40:221-228.
    PubMed    
    Abstract available

  196. KAPOOR VK
    How I Manage My Patients with Gall Bladder Cancer?
    Indian J Surg Oncol. 2024;15:652-660.
    PubMed    
    Abstract available

  197. YU Y, Zhang C, Chen H, Zhang J, et al
    Efficacy and safety analysis of neoadjuvant chemotherapy combined with immunotherapy in patients with muscle-invasive bladder cancer.
    Front Immunol. 2024;15:1479743.
    PubMed    
    Abstract available

  198. ABUHASANEIN S, Radmann J, Jahnson S, Kjolhede H, et al
    Diagnostic Performance of GeneXpert BC as a Triage Test for Patients Presenting with Macroscopic Hematuria Suspicious for Urinary Bladder Cancer: A Multicenter Prospective Case-Control Study.
    Eur Urol Open Sci. 2024;70:158-166.
    PubMed    
    Abstract available

  199. ROUANNE M, Chen N, Mariuzza DL, Li F, et al
    Tumor-specific antibodies elicited by engineered bacteria promote bladder cancer immunotherapy.
    bioRxiv [Preprint]. 2024 Oct 29:2024.10.24.620122.
    PubMed    
    Abstract available

  200. NASELLI A, Pirola GM, Castellani D
    Bacillus Calmette-Guerin (BCG) Refractory Non-Muscle-Invasive Bladder Cancer (NMIBC): Current Guidance and Experience from Clinical Practice.
    Res Rep Urol. 2024;16:299-305.
    PubMed    
    Abstract available

  201. ZHENG L, Wang J, Han S, Zhong L, et al
    The KLF16/MYC feedback loop is a therapeutic target in bladder cancer.
    J Exp Clin Cancer Res. 2024;43:303.
    PubMed    
    Abstract available

  202. ISLAM MA, Mubashshira S, Rahman MM, Kabir Y, et al
    Contribution of ERCC2 rs13181 (Lys751Gln) and rs1799793 (Asp312Asn) polymorphisms to the risk of bladder cancer in Bangladesh.
    Cancer Genet. 2024;288-289:126-132.
    PubMed    
    Abstract available

  203. ZHAO F, Xie H, Guan Y, Teng J, et al
    A redox-related lncRNA signature in bladder cancer.
    Sci Rep. 2024;14:28323.
    PubMed    
    Abstract available

  204. D'ANDREA D, Mostafid H, Gontero P, Shariat S, et al
    Unmet Need in Non-muscle-invasive Bladder Cancer Failing Bacillus Calmette-Guerin Therapy: A Systematic Review and Cost-effectiveness Analyses from the International Bladder Cancer Group.
    Eur Urol Oncol. 2024 Nov 12:S2588-9311(24)00242.
    PubMed    
    Abstract available

  205. CHUNG Y, Lee S, Jeong BC, Ku JH, et al
    Risk factors for urinary retention after robot-assisted radical cystectomy with orthotopic neobladder diversion: a multicenter study.
    J Robot Surg. 2024;19:1.
    PubMed    
    Abstract available

  206. KIM JM, Park S
    Pitfalls of frozen section diagnosis in ureter margin evaluation of plasmacytoid urothelial carcinoma of urinary bladder.
    BMC Urol. 2024;24:254.
    PubMed    
    Abstract available

  207. CHOI H, Jeong SH, Simo C, Bakenecker A, et al
    Urease-powered nanomotor containing STING agonist for bladder cancer immunotherapy.
    Nat Commun. 2024;15:9934.
    PubMed    
    Abstract available

  208. TAKEUCHI M, Higaki A, Kojima Y, Ono K, et al
    Comparative analysis of image quality and diagnostic performance among SS-EPI, MS-EPI, and rFOV DWI in bladder cancer.
    Jpn J Radiol. 2024 Nov 16. doi: 10.1007/s11604-024-01694.
    PubMed    
    Abstract available

  209. LI C, Yuan H, Chen J, Shang K, et al
    The oncogenic functions of SPARCL1 in bladder cancer.
    J Cell Mol Med. 2024;28:e70196.
    PubMed    
    Abstract available

  210. SLOTMAN E, Richters A, Fransen HP, Smilde TJ, et al
    Guidelines versus real-world data in metastatic bladder cancer: A population-based study on first-line chemotherapy treatment patterns.
    Urol Oncol. 2024 Nov 14:S1078-1439(24)00705.
    PubMed    
    Abstract available

  211. KADOURI Y, Lakssir J, Elaboudi A, El Sayegh H, et al
    A challenging case of a multiple large stones in enterocystoplasty: a case report.
    Pan Afr Med J. 2024;48:116.
    PubMed    
    Abstract available

  212. GU Y, Ly A, Rodriguez S, Zhang H, et al
    PD-1 blockade plus cisplatin-based chemotherapy in patients with small cell/neuroendocrine bladder and prostate cancers.
    Cell Rep Med. 2024;5:101824.
    PubMed    
    Abstract available

  213. ZHENG Z, Zhang S, Liu Y, Han Z, et al
    Mechanobiology studies of bladder tumor cells using laterally squeezing microfluidic flow cytometry.
    Talanta. 2025;282:127090.
    PubMed    
    Abstract available

  214. GU Y, Wang J, Luo Z, Luo X, et al
    Multiwavelength Surface-Enhanced Raman Scattering Fingerprints of Human Urine for Cancer Diagnosis.
    ACS Sens. 2024;9:5999-6010.
    PubMed    
    Abstract available

  215. MEGURO S, Johmura Y, Wang TW, Kawakami S, et al
    Preexisting senescent fibroblasts in the aged bladder create a tumor-permissive niche through CXCL12 secretion.
    Nat Aging. 2024;4:1582-1597.
    PubMed    
    Abstract available

  216. GRIFFIN J, Hartmann A, Comperat E
    Variation in cystectomy pathology reporting practice-results from an international survey of 212 pathologists.
    Virchows Arch. 2024;485:879-888.
    PubMed    
    Abstract available

  217. AKBAS P, Bektas S, Yazici G
    The association between variant histology and prognostic, histomorphological and clinical aspects of bladder urothelial carcinoma.
    Ann Diagn Pathol. 2024;73:152373.
    PubMed    
    Abstract available

  218. PINARD A, Chen C, Van Ziffle J, Simko JP, et al
    Next-generation sequencing has diagnostic utility in challenging small/flat urothelial lesions.
    Ann Diagn Pathol. 2024;73:152370.
    PubMed    
    Abstract available

  219. GRAJALES V, Lin JY, Sharbaugh D, Pere M, et al
    Factors influencing readmission patterns following radical cystectomy: An analysis of social determinants and discharge outcomes.
    Urol Oncol. 2024;42:449.
    PubMed    
    Abstract available

  220. FONTES MS
    A global view of the challenges and limitations of precision medicine for genitourinary cancers.
    Urol Oncol. 2024;42:389-391.
    PubMed    
    Abstract available

  221. YILMAZ F, Sagir S
    Prognostic and predictive value of tertiary lymphoid structures in TURBT materials: Should it be seated in the routine pathological examination, and can it be used in deciding on the treatment method?
    Urol Oncol. 2024;42:450.
    PubMed    
    Abstract available

  222. MAHMOUDPOUR SH, Knott C, Kearney M, Russo L, et al
    Factors associated with receipt of systemic anticancer treatment for locally advanced or metastatic urothelial carcinoma in England: a population-based study.
    Urol Oncol. 2024;42:451.
    PubMed    
    Abstract available

  223. DAHMEN AS, Lazarovich A, Nusbaum DJ, Katebian B, et al
    The impact of metabolic syndrome on short term radical cystectomy complications.
    Urol Oncol. 2024;42:450.
    PubMed    
    Abstract available

  224. KUMBHAM S, Rahman KMM, Bosmajian C, Bist G, et al
    Enhancing PDT efficacy in NMIBC: Efflux inhibitor mediated improvement of PpIX levels and efficacy of the combination of PpIX-PDT and SO-cleavable prodrugs.
    Photochem Photobiol. 2024;100:1636-1646.
    PubMed    
    Abstract available

  225. T O'DWYER R, Jiang DM, Kitchlu A, Coulombe AM, et al
    Management of urothelial cancer in patients with chronic kidney disease receiving platinum-based chemotherapy.
    Future Oncol. 2024;20:2889-2899.
    PubMed    
    Abstract available

  226. GALEA LA, Batrouney A, Flynn M, Christie M, et al
    POU2F3-expressing intraepithelial small-cell carcinoma with mixed small-cell carcinoma and conventional-type urothelial carcinoma of the urinary bladder.
    Virchows Arch. 2024;485:947-952.
    PubMed    
    Abstract available

  227. RAHMAN KMM, Bist G, Kumbham S, Foster BA, et al
    Mitochondrial targeting improves the selectivity of singlet-oxygen cleavable prodrugs in NMIBC treatment.
    Photochem Photobiol. 2024;100:1622-1635.
    PubMed    
    Abstract available

  228. FONTES MS, de Almeida DVP, Carcano F, Lages P, et al
    Precision medicine for urothelial carcinoma: An international perspective.
    Urol Oncol. 2024;42:402-410.
    PubMed    
    Abstract available

  229. DE JONG JJ, Proudfoot JA, Daneshmand S, Svatek RS, et al
    A luminal non-coding RNA-based genomic classifier confirms favourable outcomes in patients with clinically organ-confined bladder cancer treated with radical cystectomy.
    BJU Int. 2024 Nov 1. doi: 10.1111/bju.16572.
    PubMed    
    Abstract available

  230. DE ANGELIS M, Siech C, Di Bello F, Rodriguez Penaranda N, et al
    Mortality rates in radical cystectomy patients with bladder cancer after radiation therapy for prostate cancer.
    BJU Int. 2024 Oct 27. doi: 10.1111/bju.16571.
    PubMed    
    Abstract available

  231. PACIOTTI M, Diana P, Gallioli A, De Groote R, et al
    International consensus panel for transurethral resection of bladder tumours metrics: assessment of face and content validity.
    BJU Int. 2024;134:932-938.
    PubMed    
    Abstract available

  232. LU JL, Ye YL, Zheng DD, Shi XY, et al
    Temporal dynamics of immune cell patterns in bladder cancer patients receiving Bacillus Calmette-Guerin therapy.
    Br J Cancer. 2024 Oct 31. doi: 10.1038/s41416-024-02883.
    PubMed    
    Abstract available

  233. ALEMAN A, Adrien L, Lopez-Serra L, Cordon-Cardo C, et al
    Editorial Expression of Concern: Identification of DNA hypermethylation of SOX9 in association with bladder cancer progression using CpG microarrays.
    Br J Cancer. 2024 Nov 18. doi: 10.1038/s41416-024-02903.
    PubMed    


  234. BRIGGS LG, Parke SC, Beck KL, Sinha D, et al
    Prehabilitative/rehabilitative exercise, nutrition, and psychological support for bladder cancer: A scoping review of randomized clinical trials.
    Cancer. 2024 Nov 2. doi: 10.1002/cncr.35608.
    PubMed    
    Abstract available

  235. BRAVE MH, Maguire WF, Weinstock C, Zhang H, et al
    FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma.
    Clin Cancer Res. 2024;30:4815-4821.
    PubMed    
    Abstract available

  236. PASTORINO GL, Mercinelli C, Necchi A
    The role of MRI in muscle-invasive bladder cancer: an update from the last two years.
    Curr Opin Urol. 2024 Nov 12. doi: 10.1097/MOU.0000000000001249.
    PubMed    
    Abstract available

  237. BEN-DAVID R, Mehrazin R, Attalla K, Wiklund P, et al
    Tumor-informed circulating tumor DNA in urothelial carcinoma: a promising novel biomarker.
    Curr Opin Urol. 2024;34:464-470.
    PubMed    
    Abstract available

  238. KIEBACH J, Beeren I, Aben KKH, Witjes JA, et al
    Smoking behavior and the risks of tumor recurrence and progression in patients with non-muscle-invasive bladder cancer.
    Int J Cancer. 2024 Nov 5. doi: 10.1002/ijc.35250.
    PubMed    
    Abstract available

  239. MANN J, Niedermayer K, Krautstrunk J, Abbey L, et al
    Combined inhibition of RAD51 and CHK1 causes synergistic toxicity in cisplatin resistant cancer cells by triggering replication fork collapse.
    Int J Cancer. 2025;156:389-402.
    PubMed    
    Abstract available

  240. TSAI TF, Hwang TI, Chen PC, Chen YC, et al
    Hyperthermia reduces cancer cell invasion and combats chemoresistance and immune evasion in human bladder cancer.
    Int J Oncol. 2024;65:116.
    PubMed    
    Abstract available

  241. NAKAMURA Y, Ishikawa Y, Kobayashi M, Fujiwara M, et al
    Location-specific diagnostic efficiency of photodynamic diagnosis-guided biopsy in bladder mapping biopsies.
    Int J Urol. 2024;31:1263-1268.
    PubMed    
    Abstract available

  242. YOSHIDA S, Maezawa Y, Ishihara K, Inoue N, et al
    Outcomes and prognostic factors in patients with synchronous and metachronous oligometastatic urothelial carcinoma with visceral metastases.
    Int J Urol. 2024;31:1234-1240.
    PubMed    
    Abstract available

  243. KAYRA MV, Deniz ME, Ozer C, Guvel S, et al
    Estimation of Physiologic Ability and Surgical Stress (E-PASS) predicts postoperative complications after radical cystectomy.
    Int Urol Nephrol. 2024;56:3743-3749.
    PubMed    
    Abstract available

  244. VILLEGAS E, Lajkosz K, Din S, Kuk C, et al
    Long-term recurrence risk, metastatic potential and length of cystoscopic surveillance of low-grade non-muscle invasive bladder cancer.
    J Urol. 2024 Oct 29:101097JU0000000000004305. doi: 10.1097/JU.0000000000004305.
    PubMed    
    Abstract available


  245. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline: 2024 Amendment: Erratum.
    J Urol. 2024;212:936.
    PubMed    


  246. RAMOS P, Bras JP, Dias C, Bessa-Goncalves M, et al
    Uromonitor(R): Clinical Validation and Performance Assessment of a Urinary Biomarker within the Surveillance of Non-Muscle Invasive Bladder Cancer Patients.
    J Urol. 2024 Nov 19:101097JU0000000000004335. doi: 10.1097/JU.0000000000004335.
    PubMed    
    Abstract available

  247. PIETZAK E, Anderson CB
    What is the Standard of Care For Multifocal Low-Grade Bladder Cancer?
    J Urol. 2024 Nov 18:101097JU0000000000004316. doi: 10.1097/JU.0000000000004316.
    PubMed    


  248. HUANG T, Fan L, Tang J, Chen S, et al
    Advances in research on the carcinogenic mechanisms and therapeutic potential of YAP1 in bladder cancer (Review).
    Oncol Rep. 2025;53:10.
    PubMed    
    Abstract available

  249. SANKIN A, Dave P, Cherrill LR, Boucher RH, et al
    Low-grade Urothelial Carcinoma Recurs at a Tempo that Naturally Accelerates Over Time.
    Urology. 2024;193:166-172.
    PubMed    
    Abstract available

  250. SANCHEZ B C, Rickard M, Denburg A, Khondker A, et al
    Bladder Embryonal Rhabdomyosarcoma Presenting in the Perinatal Period: Report of Two Consecutive Cases.
    Urology. 2024;193:e85-e88.
    PubMed    
    Abstract available

  251. ABOU HEIDAR N, Mahmood AW, Khan M, Harrington G, et al
    Does Ta Low-grade Urothelial Carcinoma of the Bladder With Focal High-grade Features Carry Worse Prognosis? The Roswell Park Comprehensive Cancer Center Experience.
    Urology. 2024;193:136-142.
    PubMed    
    Abstract available

  252. FUKUMOTO W, Okamura S, Tamai M, Arima J, et al
    Development of a novel treatment based on PKMYT1 inhibition for cisplatin-resistant bladder cancer with miR-424-5p-dependent cyclin E1 amplification.
    BMC Cancer. 2024;24:1333.
    PubMed    
    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.


;